GlobeNewswire by notified

NH TherAguix Announces the completion of Phase I Recruitment for the Pancreas Cohort and the entry into Phase II in the NANOSMART phase Ib/II trial.

Share

PRESS RELEASE

NH TherAguix Announces the completion of Phase I Recruitment
for the Pancreas Cohort and the entry into Phase II
in the NANOSMART phase Ib/II trial.

  • Key clinical milestone showcasing the potential of AGuIX®, a next-generation nanodrug developed by NH TherAguix, to improve tumor targeting and augment efficacy when combined with radiotherapy in solid tumors.
  • NANOSMART is a phase Ib/II clinical trial investigating the safety and efficacy of the combination of AGuIX® intravenous injections with stereotactic magnetic resonance (MR)-guided adaptive radiation therapy for the treatment of locally advanced/unresectable pancreatic ductal adenocarcinoma (LAPC) and of centrally located non-small cell lung cancer lesions.
  • The Principal Investigator, Jonathan Leeman, MD, at Brigham & Women’s Hospital and The Dana-Farber Cancer Institute, announce the transition to the Phase II randomized part of the study in the cohort of patient with pancreatic tumors.

Paris, France, July 1st, 2024 – NH TherAguix (NHT), a phase II clinical-stage biotechnology company specializing in the development of novel nanomedicine solutions for precision radiotherapy in oncology, today announced the transition to the Phase II randomized part of the NANOSMART study in the cohort of patients with pancreatic tumors. The NANOSMART study, titled "An adaptive phase I–II trial of AGuIX® gadolinium-based nanoparticles with stereotactic magnetic resonance-guided adaptive radiation therapy (SMART) for locally advanced unresectable pancreatic ductal adenocarcinoma and centrally located lung tumors," is currently ongoing to assess safety, biodistribution and radio-enhancement efficacy of the combination of AGuIX® intravenous injections.

AGuIX®: A Nanodrug Capable of Improving the Precision and Effectiveness of Radiotherapy

The culmination of over a decade of research, AGuIX® nanoparticles are designed to meet the critical medical need for more effective cancer treatments, including pancreatic cancer. These gadolinium-based nanoparticles enhance MRI contrast, allowing for precise tumor visualization, and significantly amplify the radiation dose delivered to tumor tissues, thereby improving the efficacy of radiotherapy.

NANOSMART: A Monocentric, Randomized, Open-Label Phase Ib/II Trial Conducted with the Dana-Farber Cancer Institute/Brigham & Women’s Hospital Team

The aim of the dose escalation Phase I was to determine the recommended dose of the experimental drug to be evaluated in Phase II. Two dose levels of AGuIX® (75mg/kg and 100mg/kg) have been tested on twenty patients treated in the pancreas cohort during Phase I. These patients with locally advanced unresectable pancreatic ductal adenocarcinoma have received two injections of AGuIX® in combination with SMART (40 Gy in 5 fractions of 8 Gy). AGuIX® injections were well-tolerated. Additionally, MRI analysis has confirmed that AGuIX® nanoparticles selectively accumulated in pancreatic tumors.

A good safety profile of AGuIX® in combination with SMART was confirmed.

“The transition to the Phase II randomized stage of the study in the cohort of patients with pancreatic cancer was approved by the institutional review board and the FDA at the recommended dose of AGuIX at 100mg/kg,” said Dr Jonathan Leeman, the study P.I., from Brigham & Women’s Hospital and The Dana-Farber Cancer Institute.

The Phase II part of NANOSMART study will be randomized within two arms: an experimental arm in which patients will be treated with AGuIX® at a dose of 100 mg/kg in combination with SMART (10 patients), and a control arm in which patients will be treated with SMART alone (20 patients).

The primary endpoint of this Phase II is local control at 12 months. Secondary endpoints include progression-free survival, overall response rate, disease-specific survival, quality of life and overall survival.

Dr. Olivier de Beaumont, CMO of NH TherAguix, emphasized the significance of this step: "AGuIX® Orphan Drug Designation was already granted by FDA and EMA for pancreatic tumors in 2021, and we are very happy to be able to continue the evaluation of AGuIX® in combination with SMART after confirmation of the good safety profile and biodistribution in patients with pancreatic tumors. I would like to thank Dr. Jonathan Leeman very much for his strong commitment to enrolling patients in the two cohorts (locally advanced/unresectable pancreatic ductal adenocarcinoma (LAPC) and centrally located non-small cell lung cancer lesions.”

Vincent Carrère, CEO of NH TherAguix, commented: "We are thrilled to announce this important next step of transition to the NANOSMART Phase II randomized part in pancreatic tumors. I would like to thank Dr Jonathan Leeman and the Dana-Farber Cancer Institute/Brigham & Women’s Hospital team for this remarkable clinical and translational work. It highlights the transformative potential of AGuIX® in enhancing radiotherapy for pancreatic cancer patients. This promising next step reinforces our commitment to advancing innovative cancer treatments and improving patient outcomes in difficult-to-treat indications."

About NH TherAguix: www.nhtheraguix.com

NH TherAguix is a late-stage biotech company developing AGuIX® to treat tumors and metastases in patients undergoing radiotherapy. It is estimated that approximately 60% of cancer patients receive radiotherapy. AGuIX® is currently being assessed in multiple Phase II randomized trials across various cancer types, including brain metastases, glioblastoma, and pancreatic and lung cancers.

To date, over 190 patients have been treated with AGuIX®. This innovation is protected by 18 patent families and has been extensively tested in various preclinical models, with results published in more than 80 high-impact publications.

NH TherAguix was established in 2015 following 10 years of academic research that led to the invention of AGuIX® and the discovery of its radiosensitizing effect. The company has raised approximately €40m of funds, including a €13m Series A in 2019 led by Bpifrance with Arbevel, Omnes, and Supernova.

Media contacts:
NH TherAguix
NewCap - Arthur Rouillé
arouille@newcap.fr
+33 (0)1 44 71 00 15

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release

Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a

DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release

Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68

Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release

Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.

Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release

AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us

Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin

HiddenA line styled icon from Orion Icon Library.Eye